Literature DB >> 7979297

DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein.

M M Rayner1, B C Cordova, R P Meade, P E Aldrich, P K Jadhav, Y Ru, P Y Lam.   

Abstract

DMP 323, a C-2-symmetrical cyclic urea, is representative of a new class of inhibitors of human immunodeficiency virus protease. In this study, we correlate the potent antiviral activity of DMP 323 in acute infections with antiprotease activity assessed by monitoring the inhibition of the processing of viral gag precursor polyprotein from chronically infected lymphoid and monocytoid cell lines. Electron microscopic examination confirmed that the inhibition of gag processing was associated with the production of immature viral particles. Reduction of DMP 323 in the environment of unprocessed gag viral particles did not result in the resumption of gag processing for at least 72 h.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979297      PMCID: PMC284604          DOI: 10.1128/AAC.38.7.1635

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV).

Authors:  J S McDougal; S P Cort; M S Kennedy; C D Cabridilla; P M Feorino; D P Francis; D Hicks; V S Kalyanaraman; L S Martin
Journal:  J Immunol Methods       Date:  1985-01-21       Impact factor: 2.303

2.  Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy.

Authors:  S Koenig; H E Gendelman; J M Orenstein; M C Dal Canto; G H Pezeshkpour; M Yungbluth; F Janotta; A Aksamit; M A Martin; A S Fauci
Journal:  Science       Date:  1986-09-05       Impact factor: 47.728

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor.

Authors:  M J Otto; C D Reid; S Garber; P Y Lam; H Scarnati; L T Bacheler; M M Rayner; D L Winslow
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

7.  Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.

Authors:  P Y Lam; P K Jadhav; C J Eyermann; C N Hodge; Y Ru; L T Bacheler; J L Meek; M J Otto; M M Rayner; Y N Wong
Journal:  Science       Date:  1994-01-21       Impact factor: 47.728

8.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323.

Authors:  S Erickson-Viitanen; R M Klabe; P G Cawood; P L O'Neal; J L Meek
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  A SIMPLIFIED LEAD CITRATE STAIN FOR USE IN ELECTRON MICROSCOPY.

Authors:  J H VENABLE; R COGGESHALL
Journal:  J Cell Biol       Date:  1965-05       Impact factor: 10.539

View more
  5 in total

1.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.

Authors:  R W Humphrey; A Ohagen; D A Davis; T Fukazawa; H Hayashi; S Höglund; H Mitsuya; R Yarchoan
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages.

Authors:  David A Davis; Elizabeth Read-Connole; Kara Pearson; Henry M Fales; Fonda M Newcomb; Jackob Moskovitz; Robert Yarchoan
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions.

Authors:  D A Davis; K Yusa; L A Gillim; F M Newcomb; H Mitsuya; R Yarchoan
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

5.  Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.

Authors:  Anna Figueiredo; Katie L Moore; Johnson Mak; Nicolas Sluis-Cremer; Marie-Pierre de Bethune; Gilda Tachedjian
Journal:  PLoS Pathog       Date:  2006-11       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.